The regulation of microRNAs on chemoresistance in triple-negative breast cancer: a recent update

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Goldhirsch A, Winer EP, Coates AS et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann. Oncol. 24(9), 2206–2223 (2013).
  Medline CASGoogle Scholar
• 2. Vallejos CS, Gómez HL, Cruz WR et al. Breast cancer classification according to immunohistochemistry markers: subtypes and association with clinicopathologic variables in a peruvian hospital database. Clin. Breast Cancer 10(4), 294–300 (2010).
  MedlineGoogle Scholar
• 3. Arnedos M, Bihan C, Delaloge S et al. Triple-negative breast cancer: are we making headway at least? Ther. Adv. Med. Oncol. 4(4), 195–210 (2012).
  Medline CASGoogle Scholar
• 4. Mayer IA, Abramson VG, Lehmann BD et al. New strategies for triple-negative breast cancer–deciphering the heterogeneity. Clin. Cancer Res. 20(4), 782–790 (2014).
  Medline CASGoogle Scholar
• 5. Bergin ART, Loi S. Triple-negative breast cancer: recent treatment advances. F1000Res 8, 1342 (2019). • Suggests that chemotherapy is still the main treatment method for triple-negative breast cancer (TNBC), but it is easy to produce chemoresistance.
  CASGoogle Scholar
• 6. Romano G, Veneziano D, Acunzo M et al. Small non-coding RNA and cancer. Carcinogenesis 38(5), 485–491 (2017).
  Medline CASGoogle Scholar
• 7. Chang S, Johnston RJ Jr, Frøkjaer-Jensen C et al. MicroRNAs act sequentially and asymmetrically to control chemosensory laterality in the nematode. Nature 430(7001), 785–789 (2004).
  Medline CASGoogle Scholar
• 8. Davis BN, Hilyard AC, Nguyen PH et al. Smad proteins bind a conserved RNA sequence to promote microRNA maturation by Drosha. Mol. Cell 39(3), 373–384 (2010).
  Medline CASGoogle Scholar
• 9. Lee Y, Ahn C, Han J et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 425(6956), 415–419 (2003).
  Medline CASGoogle Scholar
• 10. Blahna MT, Hata A. Regulation of miRNA biogenesis as an integrated component of growth factor signaling. Curr. Opin. Cell Biol. 25(2), 233–240 (2013).
  Medline CASGoogle Scholar
• 11. Ding HX, Lv Z, Yuan Y et al. MiRNA polymorphisms and cancer prognosis: a systematic review and meta-analysis. Front Oncol. 8, 596 (2018).
  MedlineGoogle Scholar
• 12. Bach DH, Hong JY, Park HJ et al. The role of exosomes and miRNAs in drug-resistance of cancer cells. Int. J. Cancer 141(2), 220–230 (2017).
  Medline CASGoogle Scholar
• 13. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2), 281–297 (2004).
  Medline CASGoogle Scholar
• 14. Gebert LFR, Macrae IJ. Regulation of microRNA function in animals. Nat. Rev. Mol. Cell Biol. 20(1), 21–37 (2019).
  Medline CASGoogle Scholar
• 15. Ma J, Dong C, Ji C. MicroRNA and drug resistance. Cancer Gene Ther. 17(8), 523–531 (2010). •• Demonstrates that microRNAs play a vital role in chemoresistance.
  Medline CASGoogle Scholar
• 16. Amawi H, Sim HM, Tiwari AK et al. ABC transporter-mediated multidrug-resistant cancer. Adv. Exp. Med. Biol. 1141, 549–580 (2019).
  Medline CASGoogle Scholar
• 17. Sharom FJ. The P-glycoprotein efflux pump: how does it transport drugs? J. Membr. Biol. 160(3), 161–175 (1997).
  Medline CASGoogle Scholar
• 18. Ford RC, Beis K. Learning the ABCs one at a time: structure and mechanism of ABC transporters. Biochem. Soc. Trans. 47(1), 23–36 (2019).
  Medline CASGoogle Scholar
• 19. Vasiliou V, Vasiliou K, Nebert DW. Human ATP-binding cassette (ABC) transporter family. Hum. Genom. 3(3), 281–290 (2009).
  Medline CASGoogle Scholar
• 20. Ozben T. Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett. 580(12), 2903–2909 (2006).
  Medline CASGoogle Scholar
• 21. Chen Z, Shi T, Zhang L et al. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: a review of the past decade. Cancer Lett. 370(1), 153–164 (2016).
  Medline CASGoogle Scholar
• 22. Yamada A, Ishikawa T, Ota I et al. High expression of ATP-binding cassette transporter ABCC11 in breast tumors is associated with aggressive subtypes and low disease-free survival. Breast Cancer Res. Treat. 137(3), 773–782 (2013).
  Medline CASGoogle Scholar
• 23. Guestini F, Ono K, Miyashita M et al. Impact of Topoisomerase IIα, PTEN, ABCC1/MRP1, and KI67 on triple-negative breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res. Treat. 173(2), 275–288 (2019).
  Medline CASGoogle Scholar
• 24. Britton KM, Eyre R, Harvey IJ et al. Breast cancer, side population cells and ABCG2 expression. Cancer Lett. 323(1), 97–105 (2012).
  Medline CASGoogle Scholar
• 25. Sissung TM, Baum CE, Kirkland CT et al. Pharmacogenetics of membrane transporters: an update on current approaches. Mol. Biotechnol. 44(2), 152–167 (2010).
  Medline CASGoogle Scholar
• 26. Oguri T, Bessho Y, Achiwa H et al. MRP8/ABCC11 directly confers resistance to 5-fluorouracil. Mol. Cancer Ther. 6(1), 122–127 (2007).
  Medline CASGoogle Scholar
• 27. Fanini F, Fabbri M. MicroRNAs and cancer resistance: a new molecular plot. Clin. Pharmacol. Ther. 99(5), 485–493 (2016).
  Medline CASGoogle Scholar
• 28. Yeh WL, Tsai CF, Chen DR. Peri-foci adipose-derived stem cells promote chemoresistance in breast cancer. Stem Cell Res. Ther. 8(1), 177 (2017).
  MedlineGoogle Scholar
• 29. Zuo J, Yu Y, Zhu M et al. Inhibition of miR-155, a therapeutic target for breast cancer, prevented in cancer stem cell formation. Cancer Biomark 21(2), 383–392 (2018).
  Medline CASGoogle Scholar
• 30. O'brien C, Cavet G, Pandita A et al. Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer. Cancer Res. 68(13), 5380–5389 (2008).
  MedlineGoogle Scholar
• 31. Zeng C, Fan D, Xu Y et al. Curcumol enhances the sensitivity of doxorubicin in triple-negative breast cancer via regulating the miR-181b-2-3p-ABCC3 axis. Biochem. Pharmacol. 174, 113795 (2020). •• Indicates that overexpression of miR-181b-2-3p enhances the sensitivity of doxorubicin by inhibiting the drug efflux transporter ABCC3 in TNBC.
  Medline CASGoogle Scholar
• 32. Bao L, Hazari S, Mehra S et al. Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. Am. J. Pathol. 180(6), 2490–2503 (2012).
  Medline CASGoogle Scholar
• 33. Yi D, Xu L, Wang R et al. miR-381 overcomes cisplatin resistance in breast cancer by targeting MDR1. Cell Biol. Int. 43(1), 12–21 (2019).
  Medline CASGoogle Scholar
• 34. Simões-Wüst AP, Schürpf T, Hall J et al. Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide. Breast Cancer Res. Treat. 76(2), 157–166 (2002).
  Medline CASGoogle Scholar
• 35. Campbell KJ, Dhayade S, Ferrari N et al. MCL-1 is a prognostic indicator and drug target in breast cancer. Cell Death Dis. 9(2), 19 (2018).
  MedlineGoogle Scholar
• 36. Ozretic P, Alvir I, Sarcevic B et al. Apoptosis regulator Bcl-2 is an independent prognostic marker for worse overall survival in triple-negative breast cancer patients. Int. J. Biol. Markers 33(1), 109–115 (2018).
  Medline CASGoogle Scholar
• 37. Pan B, Yi J, Song H. MicroRNA-mediated autophagic signaling networks and cancer chemoresistance. Cancer Biother. Radiopharm. 28(8), 573–578 (2013).
  Medline CASGoogle Scholar
• 38. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 9(1), 47–59 (2008).
  Medline CASGoogle Scholar
• 39. Liu X, Tang H, Chen J et al. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer. Oncotarget 6(24), 20070–20083 (2015).
  MedlineGoogle Scholar
• 40. Hou X, Niu Z, Liu L et al. miR-1207-5p regulates the sensitivity of triple-negative breast cancer cells to Taxol treatment via the suppression of LZTS1 expression. Oncol. Lett. 17(1), 990–998 (2019).
  Medline CASGoogle Scholar
• 41. Zhang Y, Wang Y, Wei Y et al. MiR-129-3p promotes docetaxel resistance of breast cancer cells via CP110 inhibition. Sci. Rep. 5, 15424 (2015).
  Medline CASGoogle Scholar
• 42. Ouyang M, Li Y, Ye S et al. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer. PLOS ONE 9(5), e96228 (2014).
  MedlineGoogle Scholar
• 43. Perotti C, Liu R, Parusel CT et al. Heat shock protein-90-alpha, a prolactin-STAT5 target gene identified in breast cancer cells, is involved in apoptosis regulation. Breast Cancer Res. 10(6), R94 (2008).
  MedlineGoogle Scholar
• 44. Workman P, Burrows F, Neckers L et al. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann. NY Acad Sci. 1113, 202–216 (2007).
  Medline CASGoogle Scholar
• 45. O'brien K, Lowry MC, Corcoran C et al. miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity. Oncotarget 6(32), 32774–32789 (2015).
  MedlineGoogle Scholar
• 46. Yao YS, Qiu WS, Yao RY et al. miR-141 confers docetaxel chemoresistance of breast cancer cells via regulation of EIF4E expression. Oncol. Rep. 33(5), 2504–2512 (2015).
  Medline CASGoogle Scholar
• 47. Huang Z, Su GF, Hu WJ et al. The study on expression of CIAPIN1 interfering hepatocellular carcinoma cell proliferation and its mechanisms. Eur. Rev. Med. Pharmacol. Sci. 21(13), 3054–3060 (2017).
  Medline CASGoogle Scholar
• 48. Zhang YF, Li XH, Shi YQ et al. CIAPIN1 confers multidrug resistance through up-regulation of MDR-1 and Bcl-L in LoVo/Adr cells and is independent of p53. Oncol. Rep. 25(4), 1091–1098 (2011).
  Medline CASGoogle Scholar
• 49. Zhang XW, Liu L, Zhang XZ et al. Kanglaite inhibits the expression of drug resistance genes through suppressing PVT1 in cisplatin-resistant gastric cancer cells. Exp. Ther. Med. 14(2), 1789–1794 (2017).
  Medline CASGoogle Scholar
• 50. Wang XM, Gao SJ, Guo XF et al. CIAPIN1 gene silencing enhances chemosensitivity in a drug-resistant animal model in vivo. Braz. J. Med. Biol. Res. 47(4), 273–278 (2014).
  Medline CASGoogle Scholar
• 51. Deng YW, Hao WJ, Li YW et al. Hsa-miRNA-143-3p reverses multidrug resistance of triple-negative breast cancer by inhibiting the expression of its target protein cytokine-induced apoptosis inhibitor 1 in vivo. J. Breast Cancer 21(3), 251–258 (2018).
  MedlineGoogle Scholar
• 52. Chen J, Shi P, Zhang J et al. CircRNA_0044556 diminishes the sensitivity of triple-negative breast cancer cells to adriamycin by sponging miR-145 and regulating NRAS. Mol. Med. Rep. 25(2) (2022).
  Google Scholar
• 53. Tang X, Jin L, Cao P et al. MicroRNA-16 sensitizes breast cancer cells to paclitaxel through suppression of IKBKB expression. Oncotarget 7(17), 23668–23683 (2016).
  MedlineGoogle Scholar
• 54. Wang S, Oh DY, Leventaki V et al. MicroRNA-17 acts as a tumor chemosensitizer by targeting JAB1/CSN5 in triple-negative breast cancer. Cancer Lett. 465, 12–23 (2019).
  Medline CASGoogle Scholar
• 55. Ao X, Nie P, Wu B et al. Decreased expression of microRNA-17 and microRNA-20b promotes breast cancer resistance to taxol therapy by upregulation of NCOA3. Cell Death Dis. 7(11), e2463 (2016).
  Medline CASGoogle Scholar
• 56. Niu J, Xue A, Chi Y et al. Induction of miRNA-181a by genotoxic treatments promotes chemotherapeutic resistance and metastasis in breast cancer. Oncogene 35(10), 1302–1313 (2016). • Suggests that miRNA-181a promotes chemoresistance via repressing pro-apoptotic factor-BAX in TNBC.
  Medline CASGoogle Scholar
• 57. Fang H, Xie J, Zhang M et al. miRNA-21 promotes proliferation and invasion of triple-negative breast cancer cells through targeting PTEN. Am. J. Transl. Res. 9(3), 953–961 (2017).
  Medline CASGoogle Scholar
• 58. Chen L, Bourguignon LY. Hyaluronan-CD44 interaction promotes c-Jun signaling and miRNA21 expression leading to Bcl-2 expression and chemoresistance in breast cancer cells. Mol. Cancer 13, 52 (2014).
  MedlineGoogle Scholar
• 59. Luo LJ, Yang F, Ding JJ et al. MiR-31 inhibits migration and invasion by targeting SATB2 in triple-negative breast cancer. Gene 594(1), 47–58 (2016).
  Medline CASGoogle Scholar
• 60. Körner C, Keklikoglou I, Bender C et al. MicroRNA-31 sensitizes human breast cells to apoptosis by direct targeting of protein kinase C epsilon (PKCepsilon). J. Biol. Chem. 288(12), 8750–8761 (2013).
  MedlineGoogle Scholar
• 61. Shen X, Lei J, Du L. miR-31-5p may enhance the efficacy of chemotherapy with Taxol and cisplatin in TNBC. Exp. Ther. Med. 19(1), 375–383 (2020).
  Medline CASGoogle Scholar
• 62. Liu M, Gong C, Xu R et al. MicroRNA-5195-3p enhances the chemosensitivity of triple-negative breast cancer to paclitaxel by downregulating EIF4A2. Cell Mol. Biol. Lett. 24, 47 (2019).
  MedlineGoogle Scholar
• 63. Wu C, Zhao A, Tan T et al. Overexpression of microRNA-620 facilitates the resistance of triple-negative breast cancer cells to gemcitabine treatment by targeting DCTD. Exp. Ther. Med. 18(1), 550–558 (2019).
  Medline CASGoogle Scholar
• 64. Xia H, Hui KM. MicroRNAs involved in regulating epithelial–mesenchymal transition and cancer stem cells as molecular targets for cancer therapeutics. Cancer Gene Ther. 19(11), 723–730 (2012).
  Medline CASGoogle Scholar
• 65. Du C, Wang Y, Zhang Y et al. LncRNA DLX6-AS1 contributes to epithelial–mesenchymal transition and cisplatin resistance in triple-negative breast cancer via modulating Mir-199b-5p/paxillin axis. Cell Transplant. 29, 963689720929983 (2020).
  MedlineGoogle Scholar
• 66. Batlle E, Sancho E, Francí C et al. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat. Cell Biol. 2(2), 84–89 (2000).
  Medline CASGoogle Scholar
• 67. Lin LF, Li YT, Han H et al. MicroRNA-205-5p targets the HOXD9-Snail1 axis to inhibit triple-negative breast cancer cell proliferation and chemoresistance. Aging (Albany NY) 13(3), 3945–3956 (2021).
  Medline CASGoogle Scholar
• 68. Guan X, Gu S, Yuan M et al. MicroRNA-33a-5p overexpression sensitizes triple-negative breast cancer to doxorubicin by inhibiting eIF5A2 and epithelial–mesenchymal transition. Oncol. Lett. 18(6), 5986–5994 (2019). • Indicates that miR-33a-5p increases the sensitivity of TNBC to DOX by eIF5A2 and DOX-induced epithelial–mesenchymal transition.
  Medline CASGoogle Scholar
• 69. Cui N, Hu M, Khalil RA. Biochemical and biological attributes of matrix metalloproteinases. Prog. Mol. Biol. Transl. Sci. 147, 1–73 (2017).
  Medline CASGoogle Scholar
• 70. Guo J, Luo C, Yang Y et al. MiR-491-5p, as a tumor suppressor, prevents migration and invasion of breast cancer by targeting ZNF-703 to regulate AKT/mTOR pathway. Cancer Manag. Res. 13, 403–413 (2021).
  MedlineGoogle Scholar
• 71. Huang WC, Chi HC, Tung SL et al. Identification of the novel tumor suppressor role of FOCAD/miR-491-5p to inhibit cancer stemness, drug resistance and metastasis via regulating RABIF/MMP signaling in triple-negative breast cancer. Cells 10(10), 2524 (2021).
  Medline CASGoogle Scholar
• 72. Bayraktar R, Pichler M, Kanlikilicer P et al. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase. Oncotarget 8(7), 11641–11658 (2017).
  MedlineGoogle Scholar
• 73. Hamurcu Z, Ashour A, Kahraman N et al. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple-negative breast cancer cells. Oncotarget 7(13), 16619–16635 (2016).
  MedlineGoogle Scholar
• 74. Tekedereli I, Alpay SN, Tavares CD et al. Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer. PLOS ONE 7(7), e41171 (2012).
  Medline CASGoogle Scholar
• 75. Zhang P, Sun Y, Ma L. ZEB1: at the crossroads of epithelial–mesenchymal transition, metastasis and therapy resistance. Cell Cycle 14(4), 481–487 (2015).
  Medline CASGoogle Scholar
• 76. Wang G, Dong Y, Liu H et al. Loss of miR-873 contributes to gemcitabine resistance in triple-negative breast cancer via targeting ZEB1. Oncol. Lett. 18(4), 3837–3844 (2019).
  Medline CASGoogle Scholar
• 77. Pilié PG, Tang C, Mills GB et al. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat. Rev. Clin. Oncol. 16(2), 81–104 (2019).
  Medline CASGoogle Scholar
• 78. Ambrosio S, Majello B. Autophagy roles in genome maintenance. Cancers (Basel) 12(7), 1793 (2020).
  Medline CASGoogle Scholar
• 79. Chen SM, Chou WC, Hu LY et al. The effect of MicroRNA-124 overexpression on anti-tumor drug sensitivity. PLOS ONE 10(6), e0128472 (2015).
  MedlineGoogle Scholar
• 80. Fan YX, Dai YZ, Wang XL et al. MiR-18a upregulation enhances autophagy in triple negative cancer cells via inhibiting mTOR signaling pathway. Eur. Rev. Med. Pharmacol. Sci. 20(11), 2194–2200 (2016).
  MedlineGoogle Scholar
• 81. Mullan PB, Quinn JE, Harkin DP. The role of BRCA1 in transcriptional regulation and cell cycle control. Oncogene 25(43), 5854–5863 (2006).
  Medline CASGoogle Scholar
• 82. Wu J, Lu LY, Yu X. The role of BRCA1 in DNA damage response. Protein Cell 1(2), 117–123 (2010).
  MedlineGoogle Scholar
• 83. Ho JC, Chen J, Cheuk IW et al. MicroRNA-199a-3p promotes drug sensitivity in triple-negative breast cancer by down-regulation of BRCA1. Am. J. Transl. Res. 14(3), 2021–2036 (2022).
  Medline CASGoogle Scholar
• 84. Tan X, Peng J, Fu Y et al. miR-638 mediated regulation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer. Breast Cancer Res. 16(5), 435 (2014).
  MedlineGoogle Scholar
• 85. Li PP, Li RG, Huang YQ et al. LncRNA OTUD6B-AS1 promotes paclitaxel resistance in triple-negative breast cancer by regulation of miR-26a-5p/MTDH pathway-mediated autophagy and genomic instability. Aging (Albany NY) 13(21), 24171–24191 (2021).
  Medline CASGoogle Scholar
• 86. Cataldo A, Cheung DG, Balsari A et al. miR-302b enhances breast cancer cell sensitivity to cisplatin by regulating E2F1 and the cellular DNA damage response. Oncotarget 7(1), 786–797 (2016).
  MedlineGoogle Scholar
• 87. Zhong S, Ma T, Zhang X et al. MicroRNA expression profiling and bioinformatics analysis of dysregulated microRNAs in vinorelbine-resistant breast cancer cells. Gene 556(2), 113–118 (2015).
  Medline CASGoogle Scholar
• 88. Clevers H, Nusse R. Wnt/β-catenin signaling and disease. Cell 149(6), 1192–1205 (2012).
  Medline CASGoogle Scholar
• 89. Xu J, Prosperi JR, Choudhury N et al. β-Catenin is required for the tumorigenic behavior of triple-negative breast cancer cells. PLOS ONE 10(2), e0117097 (2015).
  MedlineGoogle Scholar
• 90. Yin S, Xu L, Bonfil RD et al. Tumor-initiating cells and FZD8 play a major role in drug resistance in triple-negative breast cancer. Mol. Cancer Ther. 12(4), 491–498 (2013).
  Medline CASGoogle Scholar
• 91. Li HY, Liang JL, Kuo YL et al. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple-negative breast cancer. Breast Cancer Res. 19(1), 133 (2017).
  MedlineGoogle Scholar
• 92. Wu Y, Tao L, Liang J et al. miR-187-3p increases gemcitabine sensitivity in breast cancer cells by targeting FGF9 expression. Exp. Ther. Med. 20(2), 952–960 (2020).
  Medline CASGoogle Scholar
• 93. Harrison H, Farnie G, Howell SJ et al. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res. 70(2), 709–718 (2010).
  Medline CASGoogle Scholar
• 94. Kim B, Stephen SL, Hanby AM et al. Chemotherapy induces Notch1-dependent MRP1 up-regulation, inhibition of which sensitizes breast cancer cells to chemotherapy. BMC Cancer 15, 634 (2015).
  MedlineGoogle Scholar
• 95. Li ZL, Chen C, Yang Y et al. Gamma secretase inhibitor enhances sensitivity to doxorubicin in MDA-MB-231 cells. Int. J. Clin. Exp. Pathol. 8(5), 4378–4387 (2015).
  MedlineGoogle Scholar
• 96. Qiu M, Peng Q, Jiang I et al. Specific inhibition of Notch1 signaling enhances the antitumor efficacy of chemotherapy in triple-negative breast cancer through reduction of cancer stem cells. Cancer Lett. 328(2), 261–270 (2013).
  Medline CASGoogle Scholar
• 97. Zhao M, Sun B, Wang Y et al. miR-27-3p enhances the sensitivity of triple-negative breast cancer cells to the antitumor agent olaparib by targeting PSEN-1, the Catalytic subunit of Γ-secretase. Front Oncol. 11, 694491 (2021).
  Medline CASGoogle Scholar
• 98. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490(7418), 61–70 (2012).
  MedlineGoogle Scholar
• 99. Steelman LS, Navolanic PM, Sokolosky ML et al. Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. Oncogene 27(29), 4086–4095 (2008).
  Medline CASGoogle Scholar
• 100. Pelicano H, Zhang W, Liu J et al. Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential. Breast Cancer Res. 16(5), 434 (2014).
  MedlineGoogle Scholar
• 101. Paplomata E, O'regan R. The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers. Ther. Adv. Med. Oncol. 6(4), 154–166 (2014).
  Medline CASGoogle Scholar
• 102. Zhang W, Gao Z, Guan M et al. ASF1B promotes oncogenesis in lung adenocarcinoma and other cancer types. Front Oncol. 11, 731547 (2021).
  Medline CASGoogle Scholar
• 103. Wang L, Yang X, Zhou F et al. Circular RNA UBAP2 facilitates the cisplatin resistance of triple-negative breast cancer via microRNA-300/anti-silencing function 1B histone chaperone/PI3K/AKT/mTOR axis. Bioengineered 13(3), 7197–7208 (2022).
  Medline CASGoogle Scholar
• 104. Liu MM, Li Z, Han XD et al. MiR-30e inhibits tumor growth and chemoresistance via targeting IRS1 in breast cancer. Sci. Rep. 7(1), 15929 (2017).
  MedlineGoogle Scholar
• 105. Dastmalchi N, Safaralizadeh R, Hosseinpourfeizi MA et al. MicroRNA-424-5p enhances chemosensitivity of breast cancer cells to Taxol and regulates cell cycle, apoptosis, and proliferation. Mol. Biol. Rep. 48(2), 1345–1357 (2021).
  Medline CASGoogle Scholar
• 106. Kim EK, Choi EJ. Compromised MAPK signaling in human diseases: an update. Arch. Toxicol. 89(6), 867–882 (2015).
  Medline CASGoogle Scholar
• 107. Fang JY, Richardson BC. The MAPK signalling pathways and colorectal cancer. Lancet Oncol. 6(5), 322–327 (2005).
  Medline CASGoogle Scholar
• 108. Degirmenci U, Wang M, Hu J. Targeting aberrant RAS/RAF/MEK/ERK signaling for cancer therapy. Cells 9(1), 198 (2020).
  Medline CASGoogle Scholar
• 109. Loi S, Dushyanthen S, Beavis PA et al. Correction: RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors. Clin. Cancer Res. 25(4), 1437 (2019).
  MedlineGoogle Scholar
• 110. Smith AL, Robin TP, Ford HL. Molecular pathways: targeting the TGF-β pathway for cancer therapy. Clin. Cancer Res. 18(17), 4514–4521 (2012).
  Medline CASGoogle Scholar
• 111. Neuzillet C, Tijeras-Raballand A, Cohen R et al. Targeting the TGF-β pathway for cancer therapy. Pharmacol. Ther. 147, 22–31 (2015).
  Medline CASGoogle Scholar
• 112. Xu X, Zhang L, He X et al. TGF-β plays a vital role in triple-negative breast cancer (TNBC) drug-resistance through regulating stemness, EMT and apoptosis. Biochem. Biophys. Res. Commun. 502(1), 160–165 (2018).
  Medline CASGoogle Scholar
• 113. Bhola NE, Balko JM, Dugger TC et al. TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer. J. Clin. Invest. 123(3), 1348–1358 (2013).
  Medline CASGoogle Scholar
• 114. Kumar U, Hu Y, Masrour N et al. MicroRNA-495/TGF-β/FOXC1 axis regulates multidrug resistance in metaplastic breast cancer cells. Biochem. Pharmacol. 192, 114692 (2021).
  Medline CASGoogle Scholar
• 115. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J. Pathol. 205(2), 275–292 (2005).
  Medline CASGoogle Scholar
• 116. Shibata M, Hoque MO. Targeting cancer stem cells: a strategy for effective eradication of cancer. Cancers (Basel) 11(5), 732 (2019).
  Medline CASGoogle Scholar
• 117. Creighton CJ, Li X, Landis M et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc. Natl Acad. Sci. USA 106(33), 13820–13825 (2009).
  Medline CASGoogle Scholar
• 118. Lee HE, Kim JH, Kim YJ et al. An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer. Br. J. Cancer 104(11), 1730–1738 (2011).
  Medline CASGoogle Scholar
• 119. He L, Wick N, Germans SK et al. The role of breast cancer stem cells in chemoresistance and metastasis in triple-negative breast cancer. Cancers (Basel) 13(24), 6209 (2021).
  Medline CASGoogle Scholar
• 120. Sabatier R, Charafe-Jauffret E, Pierga JY et al. Stem cells inhibition by bevacizumab in combination with neoadjuvant chemotherapy for breast cancer. J. Clin. Med. 8(5), 612 (2019).
  Medline CASGoogle Scholar
• 121. Nasr M, Farghaly M, Elsaba T et al. Resistance of primary breast cancer cells with enhanced pluripotency and stem cell activity to sex hormonal stimulation and suppression. Int. J. Biochem. Cell Biol. 105, 84–93 (2018).
  Medline CASGoogle Scholar
• 122. Vaupel P. Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis. Oncologist 13(Suppl. 3), 21–26 (2008).
  Medline CASGoogle Scholar
• 123. Gerweck LE, Vijayappa S, Kozin S. Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics. Mol. Cancer Ther. 5(5), 1275–1279 (2006). •• Indicates that the acidic tumor microenvironment caused by hypoxia reduces the intake of anticancer drugs and leads to the drug resistance.
  Medline CASGoogle Scholar
• 124. Cosse JP, Michiels C. Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. Anticancer Agents Med. Chem. 8(7), 790–797 (2008).
  Medline CASGoogle Scholar
• 125. Kim H, Lin Q, Glazer PM et al. The hypoxic tumor microenvironment in vivo selects the cancer stem cell fate of breast cancer cells. Breast Cancer Res. 20(1), 16 (2018).
  MedlineGoogle Scholar
• 126. Chouaib S, Noman MZ, Kosmatopoulos K et al. Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer. Oncogene 36(4), 439–445 (2017).
  Medline CASGoogle Scholar
• 127. Skoda AM, Simovic D, Karin V et al. The role of the Hedgehog signaling pathway in cancer: a comprehensive review. Bosn J. Basic Med. Sci. 18(1), 8–20 (2018).
  Medline CASGoogle Scholar
• 128. Harris LG, Pannell LK, Singh S et al. Increased vascularity and spontaneous metastasis of breast cancer by hedgehog signaling mediated upregulation of cyr61. Oncogene 31(28), 3370–3380 (2012).
  Medline CASGoogle Scholar
• 129. Arnold KM, Pohlig RT, Sims-Mourtada J. Co-activation of Hedgehog and Wnt signaling pathways is associated with poor outcomes in triple-negative breast cancer. Oncol. Lett. 14(5), 5285–5292 (2017).
  MedlineGoogle Scholar
• 130. Sims-Mourtada J, Opdenaker LM, Davis J et al. Taxane-induced hedgehog signaling is linked to expansion of breast cancer stem-like populations after chemotherapy. Mol. Carcinog. 54(11), 1480–1493 (2015).
  Medline CASGoogle Scholar
• 131. Slack FJ, Chinnaiyan AM. The role of non-coding RNAs in oncology. Cell 179(5), 1033–1055 (2019).
  Medline CASGoogle Scholar
• 132. Pan Y, Liu G, Zhou F et al. DNA methylation profiles in cancer diagnosis and therapeutics. Clin. Exp. Med. 18(1), 1–14 (2018).
  Medline CASGoogle Scholar
• 133. Xu Q, Jiang Y, Yin Y et al. A regulatory circuit of miR-148a/152 and DNMT1 in modulating cell transformation and tumor angiogenesis through IGF-IR and IRS1. J. Mol. Cell Biol. 5(1), 3–13 (2013).
  Medline CASGoogle Scholar
• 134. Purwanto I, Heriyanto DS, Widodo I et al. MicroRNA-223 is associated with resistance towards platinum-based chemotherapy and worse prognosis in Indonesian triple-negative breast cancer patients. Breast Cancer (Dove Med. Press) 13, 1–7 (2021). • Indicates that specific miRNAs are promising to be used as biomarkers for diagnosis.
  Medline CASGoogle Scholar
• 135. Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat. Rev. Drug Discov. 16(3), 203–222 (2017).
  Medline CASGoogle Scholar
• 136. Abd-Aziz N, Kamaruzman NI, Poh CL. Development of MicroRNAs as potential therapeutics against cancer. J. Oncol. 2020, 8029721 (2020).
  MedlineGoogle Scholar
• 137. Lin S, Gregory RI. MicroRNA biogenesis pathways in cancer. Nat. Rev. Cancer 15(6), 321–333 (2015).
  Medline CASGoogle Scholar
• 138. Seto AG, Beatty X, Lynch JM et al. Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma. Br. J. Haematol. 183(3), 428–444 (2018). • Indicates that specific miRNAs are promising to be used as biomarkers for diagnosis.
  Medline CASGoogle Scholar